Simian immunodeficiency virus (SIV) is a retrovirus that is found, in numerous strains, in primates; the specific strains infecting humans are HIV-1 and HIV-2, the viruses that cause AIDS.
George Mason University's Yuntao Wu is the lead scientist on a research team that has identified a measurable indicator that could prove instrumental in the fight against HIV.
A new study has shed light on how HIV may have evolved from the simian immunodeficiency virus (SIV) that originated in non-human primates.
Although combination antiretroviral therapy (cART) has improved survival of patients infected with HIV and has reduced the incidence of severe neurologic complications, almost half of cART-treated HIV patients experience some degree of neurocognitive impairment (neuroHIV).
According to the WHO, there are currently more than 36 million people infected with the human immunodeficiency virus (HIV) and a further 2.4 million become infected every year.
A study led by researchers at Beth Israel Deaconess Medical Center, in collaboration with scientists at Walter Reed Army Institute of Research, Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV.
Tulane University researchers found some monkeys whose immune systems are depleted by the simian strain of HIV have a second line of defense against tuberculosis.
Although antiretroviral therapy (ART) can reduce the amount of HIV in the blood to an undetectable level in most chronically infected people, it cannot eliminate reservoirs of HIV that persist in latently infected immune cells.
A new scientific study conducted by a team of leading AIDS scientists reveal results that lead the way to the development of an effective human vaccine against human immunodeficiency virus (HIV).
Vaccines are usually medicine's best defense against the world's deadliest microbes. However, HIV is so mutable that it has so far effectively evaded both the human immune system and scientists' attempts to make an effective vaccine to protect against it.
Finding the vulnerable points where HIV enters the female reproductive tract is like searching for needles in a haystack. But Northwestern Medicine scientists have solved that challenge by creating a glowing map of the very first cells to be infected with a HIV-like virus.
Scientists at Texas Biomedical Research Institute have begun work on a nearly $3.4 million study funded by the National Institutes of Health over the next four years to create an attenuated, or weakened, virus that is a hybrid of the papilloma virus and the human immunodeficiency virus, with the potential to jumpstart a body's immune response to develop antibodies against both viruses.
Two of the four known groups of human AIDS viruses (HIV-1 groups O and P) have originated in western lowland gorillas, according to an international team of scientists from the Perelman School of Medicine at the University of Pennsylvania, the University of Montpellier, the University of Edinburgh, and others.
Researchers at UC Davis have made some surprising discoveries about the body's initial responses to HIV infection. Studying simian immunodeficiency virus (SIV), the team found that specialized cells in the intestine called Paneth cells are early responders to viral invasion and are the source of gut inflammation by producing a cytokine called interleukin-1 beta (IL-1β).
The most critical barrier for curing HIV-1 infection is the presence of the viral reservoir, the cells in which the HIV virus can lie dormant for many years and avoid elimination by antiretroviral drugs. Very little has been known about when and where the viral reservoir is established during acute HIV-1 infection, or the extent to which it is susceptible to early antiretroviral therapy (ART).
HIV-1, the virus responsible for most cases of AIDS, is a very selective virus. It does not readily infect species other than its usual hosts — humans and chimpanzees.
Corneal nerve fiber assessment has great potential as a tool to diagnose and monitor peripheral neuropathy induced by HIV, say scientists at the Johns Hopkins University School of Medicine.
Scientists of the DPZ have shown that platelet activation inhibits the host cell entry of HIV. Infection biologists of the German Primate Center (DPZ) under the direction of Stefan Pöhlmann have found evidence that platelets (thrombocytes) might constitute an innate defense against infection with the human immunodeficiency virus (HIV).
Detection of HIV antibodies is used to diagnose HIV infection and monitor trials of experimental HIV/AIDS vaccines. New, more sensitive detection systems being developed use microspheres to capture HIV antibodies and can measure even small amounts of multiple antibodies at one time.
Human immunodeficiency virus (HIV) may have affected humans for much longer than is currently believed. Alfred Roca, an assistant professor in the College of Agricultural, Consumer and Environmental Sciences at the University of Illinois, thinks that the genomes of an isolated West African human population provide important clues about how the disease has evolved.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. has selected three promising Uniformed Services University of the Health Sciences (USU) doctoral students to receive fellowships for the 2012-13 academic year. The program, established in 1988, includes two Henry M. Jackson Fellowships and one Val G. Hemming Fellowship. Each fellow receives a stipend and travel support.